Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$104.7B

Apr29Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $105 billion, it plays a significant role in addressing health challenges worldwide, particularly in areas such as respiratory diseases and infectious diseases.

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and is a key metric for investors.

$1.16

Revenue

Total revenue indicates the company's overall sales performance and growth potential.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings that fell short of expectations, impacting investor sentiment. The company is focusing on strengthening its product pipeline and addressing operational efficiencies.

Management Promises & Guidance

Commitment to advancing key vaccine programs.
Focus on cost management to improve margins.
Plans to enhance R&D investments for future growth.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about GSK's upcoming earnings, with expectations for steady revenue growth but concerns about profitability.

Bull Case

If GSK meets or exceeds EPS and revenue expectations, it could signal strong operational performance and renewed investor confidence.

Bear Case

If GSK misses earnings expectations again, it may raise further concerns about its growth strategy and impact the stock negatively.

Key Metrics to Watch

EPS

$1.16

Earnings per share is crucial as it reflects the company's profitability and is a key metric for investors.

Revenue

$7.6B

Total revenue indicates the company's overall sales performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

Earnings performance is a primary driver of stock price and investor sentiment, making this a critical measure for the quarter.

What are the revenue growth expectations in key therapeutic areas?

Understanding revenue sources will help assess GSK's market position and growth potential in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to leverage its vaccine portfolio, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Options pricing suggests a higher volatility expectation than historical performance indicates.

The company's recent focus on cost management may improve margins unexpectedly.

Past earnings misses have not consistently led to prolonged negative sentiment.

Key Risk

If GSK's vaccine sales exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial for GSK, as it seeks to regain investor confidence after previous misses.

Bull Confirmed If

Achieving EPS of $1.16 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.15 would support the bear case, raising concerns about GSK's growth strategy.

Pre-Earnings Positioning

Options Market

Implied Move

±9.7%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response, as investors await further clarity on future growth strategies.

Miss

If GSK misses expectations, history suggests a potential decline of about 0.83%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and their impact on overall revenue.
2Details on cost management strategies and their expected outcomes.
3Any commentary on R&D progress and future product launches.
4Insights into market competition and GSK's positioning.
5Management's outlook on future earnings growth and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and is a key metric for investors.

$1.16

Revenue

Total revenue indicates the company's overall sales performance and growth potential.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

Management Promises & Guidance

Commitment to advancing key vaccine programs.
Focus on cost management to improve margins.
Plans to enhance R&D investments for future growth.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about GSK's upcoming earnings, with expectations for steady revenue growth but concerns about profitability.

Bull Case

If GSK meets or exceeds EPS and revenue expectations, it could signal strong operational performance and renewed investor confidence.

Bear Case

If GSK misses earnings expectations again, it may raise further concerns about its growth strategy and impact the stock negatively.

Key Metrics to Watch

EPS

$1.16

Earnings per share is crucial as it reflects the company's profitability and is a key metric for investors.

Revenue

$7.6B

Total revenue indicates the company's overall sales performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

Earnings performance is a primary driver of stock price and investor sentiment, making this a critical measure for the quarter.

What are the revenue growth expectations in key therapeutic areas?

Understanding revenue sources will help assess GSK's market position and growth potential in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to leverage its vaccine portfolio, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Options pricing suggests a higher volatility expectation than historical performance indicates.

The company's recent focus on cost management may improve margins unexpectedly.

Past earnings misses have not consistently led to prolonged negative sentiment.

Key Risk

If GSK's vaccine sales exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial for GSK, as it seeks to regain investor confidence after previous misses.

Bull Confirmed If

Achieving EPS of $1.16 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $1.15 would support the bear case, raising concerns about GSK's growth strategy.

Pre-Earnings Positioning

Options Market

Implied Move

±9.7%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to a muted response, as investors await further clarity on future growth strategies.

Miss

If GSK misses expectations, history suggests a potential decline of about 0.83%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and their impact on overall revenue.
2Details on cost management strategies and their expected outcomes.
3Any commentary on R&D progress and future product launches.
4Insights into market competition and GSK's positioning.
5Management's outlook on future earnings growth and market conditions.